| CUSIX | VISVX | CUSIX / VISVX | |
| Total Expense Ratio | 1.00 | 0.19 | 526% |
| Annual Report Gross Expense Ratio | 4.22 | 0.19 | 2,221% |
| Fund Existence | 17 years | 28 years | - |
| Gain YTD | 13.725 | 17.881 | 77% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 1000000 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 10M | 68.3B | 0% |
| Annual Yield % from dividends | 1.28 | 1.65 | 78% |
| Returns for 1 year | 13.15 | 23.48 | 56% |
| Returns for 3 years | 27.60 | 54.68 | 50% |
| Returns for 5 years | 7.20 | 50.65 | 14% |
| Returns for 10 years | 34.34 | 133.26 | 26% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| SHPAX | 23.98 | 0.24 | +1.01% |
| Saratoga Health & Biotechnology A | |||
| GQJIX | 12.86 | 0.08 | +0.63% |
| GQG Partners Intl Qual Val Fd Ins | |||
| DMCFX | 32.44 | 0.17 | +0.53% |
| Invesco Discovery Mid Cap Growth R5 | |||
| GRMIX | 34.66 | 0.15 | +0.43% |
| Nationwide S&P 500 Index R6 | |||
| TNXIX | 23.19 | 0.09 | +0.41% |
| 1290 Avantis U.S. Large Cap Growth I | |||